ERK activity as a key player in determining cardiac cell fate choices

This study demonstrates that alternating ERK activity pulses within the lateral plate mesoderm act as a critical determinant of cardiac cell fate, where inhibiting this signaling pathway prior to commitment shifts progenitor differentiation away from first heart field cardiomyocytes toward second heart field and juxta-cardiac field (epicardial) lineages.

The Gist

The Big Picture: A Construction Site with a Master Switch

Imagine the developing human heart as a massive construction site. At the very beginning, you have a pile of raw materials (stem cells) that could become anything: the walls (heart muscle), the plumbing (blood vessels), or the electrical wiring (pacemakers).

For a long time, scientists knew that a specific chemical signal called FGF (which triggers a pathway known as ERK) acts like a foreman shouting, "Build the walls!" This signal pushes cells to become First Heart Field (FHF) cells, which turn into the main pumping chambers of the heart (the left ventricle).

However, this paper asks a fascinating question: What happens if we tell the foreman to take a coffee break?

The researchers, Karin Farkas and Elisabetta Ferretti, decided to temporarily silence this "build the walls" signal in human stem cells growing in a lab dish. They found that when they paused this signal at just the right moment, the cells didn't stop building; instead, they switched plans. They stopped trying to become heart muscle and started becoming proepicardial cells (the "foremen" that build the heart's outer skin and blood vessels) and other specialized helpers.

The Story in Three Acts

Act 1: The "Coffee Break" Experiment

The scientists took human stem cells and guided them to become heart cells.

• The Control Group (The Standard Plan): They let the cells follow the natural path. The cells became a mesh of beating heart muscle, like a rhythmic drumline.
• The Experiment Group (The Coffee Break): For just 24 hours, they added a chemical "brake" (called PD0325901) that stopped the ERK signal. It was like hitting the pause button on the "make muscle" instruction.

The Result: When the brake was released, the cells didn't go back to being muscle. Instead, they changed their identity. They stopped beating in a wave and started twitching individually. More importantly, their genetic "blueprints" changed. They turned off the genes for heart muscle and turned on the genes for the proepicardium (the heart's protective outer layer) and the Second Heart Field (which builds the right side of the heart and the outflow tract).

Act 2: The "Pulse" Theory

Why does a short pause cause such a big change?
The paper suggests that the ERK signal doesn't just flow like a river; it pulses like a heartbeat. Think of it like a metronome for a band. The rhythm of the signal tells the cells what to do.

• Continuous signal: "Keep building muscle!"
• Interrupted signal: "Wait, switch to building the outer shell and blood vessels!"

The researchers found that even a short 24-hour interruption was enough to permanently reprogram the cells. It's as if the cells heard the metronome skip a beat and decided to play a completely different song.

Act 3: 2D vs. 3D (The Flat vs. The Ball)

The scientists tested this in two ways:

1. Flat dishes (2D): Cells spread out like a pancake. The switch was very clear here.
2. 3D Organoids (Balls of cells): Cells clumped together like a tiny marble. This mimics the real body better.
   Even in the 3D "marbles," the cells switched to becoming proepicardial cells, though the change was a bit more mixed. This proves the method works even in a complex, 3D environment, which is crucial for making real tissues for medicine.

Why This Matters: The "Healing Skin" of the Heart

Why do we care about these proepicardial cells?

Imagine your heart is a house. The heart muscle is the bricks, but the epicardium is the roof and the siding.

• In a healthy heart: The epicardium is like a construction crew that helps the bricks grow and arrange themselves correctly.
• In a damaged heart: When a heart attack happens, the "roof" gets damaged. The body tries to fix it, but often just puts up a scar (fibrosis) instead of new tissue.

Scientists believe that if we can grow these proepicardial cells in a lab and put them back into a damaged heart, they might act like a "regenerative crew." They could help the heart muscle heal, grow new blood vessels, and reduce scarring.

The Takeaway

This paper is like discovering a secret shortcut in a video game.

• Old way: To get the "Proepicardium" character, you had to follow a long, complicated quest (using different chemicals over many days).
• New way: The researchers found that if you just hit the "Pause" button on the ERK signal for one day, the game automatically unlocks the Proepicardium character.

In simple terms: By briefly turning off the signal that tells cells to become heart muscle, the scientists successfully tricked the cells into becoming the "healers" of the heart. This could lead to faster, better ways to grow heart tissue for patients with heart disease, potentially helping to repair damaged hearts in the future.

Technical Summary

1. Problem Statement

Heart development relies on the precise spatial and temporal specification of diverse cell lineages originating from the lateral plate mesoderm (LPM), including the First Heart Field (FHF), Second Heart Field (SHF), and the proepicardium (which gives rise to the epicardium). While the Fibroblast Growth Factor (FGF)-MEK-ERK signaling pathway is known to be crucial in development, its specific role in early cardiac lineage specification remains elusive.

• The Gap: It is unclear how the temporal modulation of ERK activity (specifically the pulsing nature of the pathway) influences binary cell fate decisions between cardiomyocytes (FHF) and extra-cardiac lineages (proepicardium/SHF).
• The Goal: To determine if transient inhibition of the MEK/ERK pathway at the LPM stage can redirect cell fate away from FHF-like cardiomyocytes toward proepicardial and SHF progenitors.

2. Methodology

The authors utilized human embryonic stem cells (hESCs, line H9) differentiated into cardiac lineages using a chemically defined, stepwise protocol.

• Differentiation Models:
  • 2D Monolayer: Cells were differentiated in a monolayer culture to minimize variability.
  • 3D Organoids: Cells were aggregated into embryoid bodies to mimic physiological 3D architecture.
• Experimental Intervention:
  • Cells were differentiated to the LPM stage (Day 2).
  • Treatment: On Day 3, cells were treated for 24 hours with PD0325901 (PD), a potent allosteric MEK inhibitor, to block ERK phosphorylation.
  • Controls: Control cultures received FGF2 (standard protocol) or were treated with PD in the presence of FGF2 to distinguish between MEK inhibition and FGF withdrawal effects.
• Analytical Techniques:
  • Morphology: Live-cell imaging to assess beating patterns (Day 8).
  • Western Blotting: To verify the duration of ERK pathway inhibition (pMEK/pERK levels) from Day 2 to Day 8.
  • Bulk RNA Sequencing (RNA-seq): Performed on Day 8 samples (2D and 3D) to analyze global transcriptomic shifts.
  • Single-Cell RNA Sequencing (scRNA-seq): Conducted on Day 2, Day 3, and Day 8 samples to resolve cell heterogeneity and differentiation trajectories.
  • Immunofluorescence: Validation of protein markers (WT1, TBX18, TNNT2, ACTA2) in both 2D and 3D cultures.
  • Comparative Analysis: Integration of their scRNA-seq data with published in vivo fetal epicardium datasets and existing in vitro epicardial differentiation protocols.

3. Key Results

A. Phenotypic and Transcriptomic Shifts

• Morphology: Control cultures formed a continuous, mesh-like network of beating cardiomyocytes. In contrast, PD-treated cultures exhibited isolated twitching structures, suggesting a loss of synchronized cardiomyocyte maturation.
• Gene Expression (Bulk RNA-seq):
  • Upregulation in PD-treated cells: Proepicardial markers (WT1, TBX18, TCF21, SEMA3D, TNNT1), Juxta-cardiac field (JCF) marker (MAB21L2), and pharyngeal/SHF markers (PITX2, LHX2).
  • Downregulation in PD-treated cells: FHF and cardiomyocyte markers (MYH6, MYH7, TNNT2, NKX2.5, IRX4, ACTA2).
  • Mechanism Validation: The shift occurred regardless of FGF2 presence (PD+FGF2 vs. PD alone), confirming the effect was driven by MEK/ERK inhibition rather than FGF withdrawal.
• Protein Validation: Immunofluorescence confirmed that PD-treated cells expressed WT1 and TBX18 (proepicardial) but lacked TNNT2 (cardiomyocyte), whereas controls showed the inverse pattern.

B. Dynamics of Inhibition

• Western blotting revealed that a single 24-hour PD treatment caused an immediate accumulation of pMEK and a rapid vanishing of pERK. Crucially, low pERK levels persisted until at least Day 4 (one day after drug removal), indicating a sustained downstream effect of transient inhibition.

C. Single-Cell Resolution

• Trajectory: scRNA-seq showed that PD treatment enriched for cells expressing early proepicardial markers (WT1) as early as Day 3.
• Lineage Identity: By Day 8, PD-treated cells clustered with progenitors expressing SHF markers (NR2F1, KCNJ3) and pacemaker markers (HCN1), in addition to proepicardial markers.
• Comparison to In Vivo: When integrated with published in vivo fetal epicardium data, the Day 8 PD-treated cells showed comparable or superior expression of epicardial markers (WT1, TBX18) compared to previously published in vitro protocols (e.g., the BWR protocol).

D. 2D vs. 3D Differences

• While both 2D and 3D cultures showed a shift toward proepicardial identity, 3D organoids exhibited upregulation of genes associated with anti-proliferation and anti-migration (e.g., SFRP1, NPPA), suggesting that 3D architecture modulates the specific transcriptional response to ERK inhibition.

4. Key Contributions

1. Novel Fate Switch Mechanism: The study establishes that transient inhibition of the MEK/ERK pathway at the LPM stage is sufficient to switch cell fate from FHF-like cardiomyocytes to a broader progenitor pool including proepicardium, SHF, and JCF.
2. Optimized Protocol for Proepicardium: The authors provide a faster, more robust protocol for deriving proepicardial cells from hESCs compared to existing methods that rely heavily on complex WNT modulation.
3. Validation of In Vitro Models: The PD-derived cells demonstrate a transcriptomic profile that closely mimics in vivo fetal epicardium, surpassing previous in vitro models in marker expression fidelity.
4. Insight into ERK Pulsing: The findings support the hypothesis that the temporal dynamics (pulses) of ERK activity act as an intrinsic clock for cell fate determination in the cardiac lineage.

5. Significance and Future Implications

• Regenerative Medicine: The epicardium is critical for heart regeneration, providing signals for cardiomyocyte proliferation and maturation. The ability to efficiently generate high-quality proepicardial progenitors using this protocol could enhance stem cell-based therapies for myocardial infarction.
• Disease Modeling: These cells offer a superior platform for modeling congenital heart defects related to epicardial or SHF development and for studying the mechanisms of cardiac fibrosis.
• Developmental Biology: The study clarifies the crosstalk between FGF-MEK-ERK and WNT signaling pathways, suggesting that ERK inhibition may functionally mimic or synergize with WNT inhibition in directing epicardial fate.

Conclusion: The paper demonstrates that ERK activity is a decisive factor in cardiac lineage specification. By transiently inhibiting this pathway, researchers can effectively "reprogram" differentiating stem cells away from the ventricular lineage toward a proepicardial and SHF fate, offering a powerful new tool for cardiac regenerative medicine.